Menin Reset
A study published October 12, 2026 found that Menin — a transcriptional scaffold encoded by MEN1 — progressively declines with age, destabilizing the KMT2A/MLL1 complex and disrupting Wnt, TGF-β, and IGF-1 signaling in stem cells. Restoring Menin in 22-month-old mice reversed gut regeneration failure, sarcopenia, and glucose intolerance. Toggle the switch to watch 32 cells age and rejuvenate.
Menin was first characterized as the product of the MEN1tumor suppressor gene — its loss causes multiple endocrine neoplasia type 1. For decades it was studied as a cancer gene. The 2026 aging study reframed it: Menin's normal job is to scaffold the KMT2A/MLL1 histone methyltransferase complex onto chromatin, writing activating H3K4me3 marks at promoters required for stem cell self-renewal and metabolic homeostasis.
As Menin falls in aged tissue, the transcription factor FOXA2 loses access to its target promoters. Wnt ligand production drops; the intestinal crypt niche can no longer support ISC proliferation; muscle satellite cells fail to activate after micro-injury. The key finding: restoring Menin via an MLLT3-targeting agonist in 22-month-old mice (≈ 65-year-old human) reversed all three hallmarks — gut regeneration, muscle mass, glucose tolerance — within weeks, with no observed tumor formation.